Italy

Evotec expands cell therapy manufacturing with acquisition

31-May-2022 By Ben Hargreaves

Evotec agrees to acquire Rigenerand, which adds a manufacturing facility capable of producing cell therapies to its infrastructure in Italy.

Donaldson Company strengthens presence in biopharma with Solaris Biotechnology acquisition

23-Nov-2021 By Rachel Arthur

Donaldson Company, Inc., a global provider of filtration products and solutions, has acquired Solaris Biotechnology Srl for around €41m ($46m).

CPHI WORLDWIDE

Hybrid CPhI Worldwide 2021 a ‘celebration’ of pharma industry

02-Nov-2021 By Jenni Spinner

The global pharmaceutical industry event is returning to the real world November 9-11 this year, with online content for professionals opting not to travel.

ReiThera’s COVID-19 vaccine looks to Phase 3 trial after preliminary Phase 2 data

12-Jul-2021 By Rachel Arthur

Antibody responses against the SARS-CoV-2 spike protein were found in 99% of volunteers after the second dose of ReiThera’s COVID-19 vaccine candidate, according to Phase 2 preliminary data.

AstraZeneca hits out against ‘inaccurate statements’ on COVID-19 vaccine supplies from Italian plant

25-Mar-2021 By Rachel Arthur

As tensions over COVID-19 vaccine supplies in Europe continue, AstraZeneca clarifies that a set of doses at its Anagni plant in Italy are destined for the EU and COVAX.

Bristol-Myers offloads manufacturing plant to Catalent

13-Jan-2020 By Nick Taylor

Catalent buys Italian manufacturing and packaging plant from Bristol-Myers Squibb, adding oral solid, biologics and sterile product capacity.

UPDATED

Catalent continues expansion spree with BMS manufacturing facility

19-Jun-2019 By Ben Hargreaves

Catalent to purchase BMS’s Italian manufacturing facility to gain access to fill/finish capabilities, following several large-scale deals this year.

EU rules Avastin can be reimbursed for off-label use

30-Nov-2018 By Maggie Lynch

The European Court of Justice has determined that Roche’s Avastin may be reimbursed for ARMD – despite Novartis and Bayer’s challenge.